Literature DB >> 3090379

Cost-effectiveness of the North Karelia Hypertension Program. 1972-1977.

A Nissinen, J Tuomilehto, T E Kottke, P Puska.   

Abstract

The North Karelia Hypertension Program was initiated in 1972 as part of the North Karelia Project. This article examines the costs and effects of the first 5 years of the project. There were 288 fewer than expected fatal strokes and myocardial infarctions during the period; 134 of these are attributable to the hypertension program. The costs of the hypertension program totalled $5.16 million. Drugs consumed 86% of this cost. Using the zero discount rate as an outside boundary, the program is expected to increase old age pension costs by $2.5 million for the 5 years but will decrease earnings losses by $7 million for the same period. With earnings excluded, the cost per quality-adjusted life-year gained is $3,612 at zero discount and $5,830 at 10% discount. Hypertension care is more cost-effective than many of the treatments applied after the appearance of coronary heart disease symptoms but would be much more cost-effective if hypertension could be treated as effectively without medications or if the costs of medications could be reduced.

Entities:  

Mesh:

Year:  1986        PMID: 3090379     DOI: 10.1097/00005650-198608000-00012

Source DB:  PubMed          Journal:  Med Care        ISSN: 0025-7079            Impact factor:   2.983


  18 in total

Review 1.  Pharmacoeconomics of hypertension management: the place of combination therapy.

Authors:  E Ambrosioni
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

2.  Initiation and maintenance of patient behavioral change: what is the role of the physician?

Authors:  T E Kottke; L I Solberg; M L Brekke
Journal:  J Gen Intern Med       Date:  1990 Sep-Oct       Impact factor: 5.128

3.  The reliability of cost-utility estimates in cost-per-QALY league tables .

Authors:  S Petrou; M Malek; P G Davey
Journal:  Pharmacoeconomics       Date:  1993-05       Impact factor: 4.981

Review 4.  Costs of illness in cost-effectiveness analysis. A review of the methodology.

Authors:  T A Hodgson
Journal:  Pharmacoeconomics       Date:  1994-12       Impact factor: 4.981

Review 5.  Improved treatment capacity and quality of care: the effectiveness of the stroke prevention and treatment system in Shanghai, China from 2012-2017.

Authors:  Bifan Zhu; Duo Chen; Chunlin Jin; Peipei Song; Fen Li
Journal:  Glob Health Med       Date:  2020-02-29

6.  A review of cost-effectiveness analyses of hypertension treatment.

Authors:  M Johannesson; B Jönsson
Journal:  Pharmacoeconomics       Date:  1992-04       Impact factor: 4.981

Review 7.  Metoprolol: a pharmacoeconomic and quality-of-life evaluation of its use in hypertension, post-myocardial infarction and dilated cardiomyopathy.

Authors:  D H Peters; P Benfield
Journal:  Pharmacoeconomics       Date:  1994-10       Impact factor: 4.981

8.  Cancer risks in perspective.

Authors:  P Reizenstein
Journal:  Med Oncol Tumor Pharmacother       Date:  1987

9.  Effects of interventions on community awareness and treatment of hypertension: results of a WHO study.

Authors:  G B Ambrosio; T Strasser; J E Dowd; J Tuomilehto; A Nissinen; A Froment; H Milon; J M Miguel; I Macias-Castro; N Dondog
Journal:  Bull World Health Organ       Date:  1988       Impact factor: 9.408

Review 10.  Economics of hypertension control. World Hypertension League.

Authors: 
Journal:  Bull World Health Organ       Date:  1995       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.